Latest filings (excl ownership)
6-K/A
Condensed consolidated interim financial statements
19 Aug 24
6-K
Current report (foreign)
15 Aug 24
6-K
Current report (foreign)
15 Aug 24
6-K/A
Current report (foreign) (amended)
14 Aug 24
6-K
Condensed consolidated interim financial statements
14 Aug 24
6-K
FSD Pharma Announces Share Consolidation and Name Change
12 Aug 24
6-K
Current report (foreign)
9 Aug 24
6-K
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
29 Jul 24
6-K
Annual General and Special Meeting of the Shareholders to Be Held on Management Information Circular
8 Jul 24
6-K
Amended and Restated Material Change Report
8 Jul 24
6-K
FSD Pharma provides Corporate Update
28 Jun 24
6-K
Current report (foreign)
28 Jun 24
6-K
Current report (foreign)
27 Jun 24
6-K
Current report (foreign)
13 Jun 24
6-K
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd™ in Acute Alcohol Intoxication
4 Jun 24
6-K
Current report (foreign)
31 May 24
6-K
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd™ in Acute Alcohol Intoxication
28 May 24
6-K
FSD Pharma Provides Corporate Update
24 May 24
6-K
Current report (foreign)
16 May 24
6-K
Condensed consolidated interim financial statements
15 May 24
6-K
Current report (foreign)
7 May 24
6-K
Current report (foreign)
30 Apr 24
6-K
Current report (foreign)
25 Apr 24
6-K
Current report (foreign)
22 Apr 24
6-K
Current report (foreign)
17 Apr 24
6-K
FSD Pharma announces Filing of Year-End 2023 Results
15 Apr 24
6-K
Current report (foreign)
15 Apr 24
6-K
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
9 Apr 24
20-F
2023 FY
Annual report (foreign)
1 Apr 24
6-K
Current report (foreign)
27 Mar 24
6-K
Current report (foreign)
11 Mar 24
6-K
Current report (foreign)
5 Mar 24
6-K
FSD Pharma Announces Debt Settlement
28 Feb 24
6-K
Current report (foreign)
26 Feb 24
6-K
Current report (foreign)
21 Feb 24
6-K
FSD Pharma Announces US ATM Offering
20 Feb 24
6-K
FSD Pharma Announces US ATM Offering
20 Feb 24
424B5
Prospectus supplement for primary offering
16 Feb 24
6-K
FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates
7 Feb 24
6-K
FSD Pharma Awards Total Approximately $3 Million
7 Feb 24